Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RXFP1 | Q9HBX9 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 5/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | GAA | P10253 | 2/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.43 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.43 |
| ▸ | LMNA | P02545 | 3/20 | 0.41 |
| ▸ | RAB9A | P51151 | 3/20 | 0.40 |
| ▸ | HTT | P42858 | 2/20 | 0.39 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5923350 | 0.89 | HTT (0.43) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5923048 | 0.86 | RXFP1 (0.46) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5923330 | 0.83 | RXFP1 (0.46) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5922980 | 0.83 | RXFP1 (0.46) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5923436 | 0.83 | RXFP1 (0.46) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5923367 | 0.80 | ALDH1A1 (0.48) | RXFP1MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL5923331 | 0.75 | RAB9A (0.48) | RXFP1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL5923511 | 0.74 | SMN1; SMN2 (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL14862600 | 0.74 | HDAC1 (0.53) | MAPTALDH1A1MEN1KMT2AKDM4E | |
| SCHEMBL5923062 | 0.72 | ALDH1A1 (0.54) | MAPTALDH1A1KMT2AGAAKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | claimed |
| WO-2005095345-A2 | HETEROARYL GUANIDINES AS INHIBITORS OF VIRAL REPLICATION | ACHILLION PHARMACEUTICALS, INC. (US) | 2005-10-13 | — | — | WO | claimed |
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | ACHILLION PHARMACEUTICALS, INC. | 2006-05-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060100225-A1 | Heteroaryl guanidines; inhibitors of viral replication | PIGS, GUCY1A1, GUCY1B1 | RXFP1 235/4885MAPT 2982/4885ALDH1A1 535/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.